Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production.
## Primary Indications
* Gastroesophageal reflux disease (GERD)
* Healing of erosive esophagitis
* Treatment of duodenal ulcers
* Treatment of gastric ulcers
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
## Adult Dosing
* **GERD and Erosive Esophagitis:** 40 mg orally or intravenously (IV) once daily for up to 8 weeks. Maintenance therapy: 20-40 mg once daily.
* **Duodenal Ulcers:** 40 mg orally once daily for 7 days.
* **Gastric Ulcers:** 40 mg orally once daily for 4 to 8 weeks.
* **Pathological Hypersecretory Conditions:** Starting dose: 40 mg orally or IV twice daily. Doses may be increased. Maximum dose: 240 mg/day.
## Pediatric Dosing
* **GERD (6 months to 16 years):**
* **Erosive Esophagitis:** 1.25 mg/kg/day orally, divided into two doses, up to a maximum of 40 mg/day.
* **Symptomatic GERD:** 1.25 mg/kg/day orally once daily, up to a maximum of 20 mg/day.
* *Note: IV dosing in pediatrics is not well established and should be guided by specialist recommendation.*
## Dose Adjustments
* **Hepatic Impairment:** Maximum dose of 20 mg orally or IV once daily.
* **Renal Impairment:** No dosage adjustment necessary.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
Common: Headache, diarrhea, nausea, abdominal pain, dizziness, flatulence.
Less common/Serious: Bone fracture (hip, wrist, spine) with prolonged use, *Clostridium difficile*-associated diarrhea, hypomagnesemia, vitamin B12 deficiency, fundic gland polyps.
## Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** Ketoconazole, itraconazole, iron salts, mycophenolate mofetil, nilotinib. Pantoprazole may decrease absorption.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **CYP2C19 substrates:** Clopidogrel (reduced antiplatelet effect), voriconazole (increased voriconazole levels).
* **CYP3A4 substrates:** Monitor for changes in levels of drugs like tacrolimus, diazepam.
## Monitoring
* Electrolytes (especially magnesium), particularly with prolonged therapy or concurrent diuretic use.
* For signs and symptoms of *Clostridium difficile*-associated diarrhea.
* Bone mineral density screening for patients at risk of osteoporosis with long-term therapy.
* Vitamin B12 levels with prolonged therapy.
## Clinical Pearls
* Administer oral pantoprazole 30-60 minutes before a meal.
* IV pantoprazole is generally reserved for situations where oral administration is not possible or clinically indicated.
* Long-term PPI use is associated with potential risks; consider de-escalation or discontinuation when appropriate.
* While pantoprazole is generally considered to have fewer CYP2C19 interactions compared to omeprazole/esomeprazole, caution is still advised with clopidogrel.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional protocols for complete details before making clinical decisions.*
